News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Lack of effective treatments for blood cancer patients

Lack of access to effective treatments is forcing blood cancer patients to take desperate measures

12 April 2018

Lack of funded access to life-extending treatments for multiple myeloma is causing some New Zealand patients to take desperate measures, including importing cheap, potentially less effective ‘knock-offs’ of the drug Lenalidomide from India, and in some cases even moving to Australia where another new myeloma treatment (Daratumumab) which is not funded here is available on a compassionate access programme.

Haematologist and chief executive of Myeloma New Zealand Charitable Trust Dr Ken Romeril says very few patients can afford the $100,000.00 it costs per year to receive Daratumumab, which has shown significant gains in survival for myeloma patients.

“It is not illegal to import generic drugs from India, but there are serious questions around the efficacy of some of these generic drugs.

“Getting onto drug trials in New Zealand has been another option for patients seeking access to novel agents, but often the trials are only open for a short time.

“A further issue is that not all centres in NZ have the trials open at their sites, forcing patients to try to travel to another region where a DHB may be offering a trial. Part of the problem is that drug trials require a lot of paperwork and oversight, and are therefore not all that well supported by some of the DHBs.

“While these issues are challenging for the health system, it is the patients whose interests we should be considering here, many of whom have run out of options and whose very survival is in the balance,” said Dr Romeril.

Multiple myeloma is a blood cancer of malignant plasma cells and is now the second commonest and second fastest growing blood cancer in the world.

Each year around 380 New Zealanders will develop this serious condition, and around 1800 are currently living with it.

Dr Romeril said that from 2011 New Zealand had been able to get access to Bortezomib, a new drug that improved the average survival from 3 to 4 years to around 6 to 7 years.

“New Zealand managed to achieve funded access to Bortezomib before Australia and we were leading them in terms of patient survival. But Australia has since made gains with improved access to a Thalidomide spin-off named Lenalidomide and have also been able to offer relapsed patients a compassionate programme for Daratumamab, which is proving very effective.

“So once again we are slipping behind Australia, and while it’s not surprising that some New Zealand patients have managed to move to Australia to get the drug, that’s not an option open to most of our patients.

battling myeloma and find the money to widen access to this and other more effective myeloma drugs, so that we can continue to build on the gains achieved over the last decade,” said Dr Romeril.

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Book cover: New Zealand's Backyard BeastsScoop Review Of Books: Bug Report

You might be forgiven for being a little uncertain about what this non-fiction work is all about based just on its title, but the cover illustration steers you straight, and the content inside leaves you in no doubt about the purpose of this lovely book More>>

Gordon Campbell: On The Best Music Tracks Of 2018

Oliver Godji, who records as Octavian, is a French/British/Angolan rapper based in London. As someone born in Lille, France, he didn’t qualify for welfare in Britain... More>>

Programme Launch: Pussy Riot Leads The Auckland Fringe

The full programme for Auckland Fringe arts festival 2019 has landed with a giant international announcement for the blockbuster programme which features Russian protest art collective Pussy Riot. They are set to make their New Zealand debut, coming to Auckland for one night only. More>>

Howard Davis: Three Reasons for Film Fans to Get Netflix

The past two months have finally seen Netflix come into its own, providing the financing for three films that will warm the hearts of cinephiles everywhere - Orson Welles' The Other Side of The Wind, The Coen Brothers' The Ballad of Buster Scruggs, and Alfonso Cuarón's Roma. More>>

Scoop Review Of Books: The Rift by Rachael Craw

Rachael Craw's first series, Spark has been extremely well received by the YA community in both Australia and New Zealand (it has a hashtag, #SparkArmy), and The Rift looks like it’s going to be just as popular. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland